Login
Companies $PGEN
$4.33 +$0.03 (0.7%) After hours
PRECIGEN, INC. logo

PRECIGEN, INC.

precigen.com

What Do They Do?

Sells Papzimeos, an immunotherapy for adults with recurrent respiratory papillomatosis, and develops therapies for cancer and other diseases; also sells miniature swine research models and services to healthcare researchers.

How Do They Make Money?

Specialty distributors buy Papzimeos for medical centers, hospitals and specialty pharmacies, with payment due after sale. Exemplar sells miniature swine models and related research services, with product sales at a point in time and service revenue as the work is provided.

revenue
SegmentShareRevenue
Product revenues, net
Sold outright

41%
Service revenues
Recurring

40%

Who Are Their Customers?

Medical centers, hospitals and specialty pharmacies obtain Papzimeos through specialty distributors; industry and academic researchers use Exemplar's models and services.

Do Revenues Turn Into Profits?

No. It lost $250.6M in FY2025.

Operating income, FY2025
−1141% of revenue
▲ +18% (Loss) vs FY2024 (−$135M, −3440%)
Net income, FY2025
−2588% of revenue
▼ −99% (Loss) vs FY2024 (−$126.2M, −3216%)
Free cash flow, FY2025
−928% of revenue
▼ −17% (Loss) vs FY2024 (−$76.8M, −1956%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +2438%
vs $2.9M in Q3 FY2025
Net income
▲ Turned profitable
vs −$146.3M in Q3 FY2025
Product revenues, net share of revenue vs 5.5% in Q3 FY2025

Shrinking. Revenue fell 32% in 4 years, from $14.3M in FY2021 to $9.7M in FY2025, about 9% a year.

Commercial product sales The older report described a discovery- and clinical-stage drug developer; the latest describes a commercial-stage biopharma company with an approved Papzimeos product for adults with recurrent respiratory papillomatosis, alongside a development pipeline.

Revenue over time
Product revenues, net Service revenues Product and Service Papzimeos Exemplar Exemplar
$10M$5M$0

Who Do They Compete With?

Competes with INOVIO Pharmaceuticals, BioNTech, PDS Biotechnology, NeoTrail Therapeutics, Nykode Therapeutics, ViciniVax, Bavarian Nordic, Kite, Iovance, Bristol-Myers Squibb, Merck, Regeneron Pharmaceuticals, Anixa Biosciences, US WorldMeds, Essen Biotech, Senti Bio, Allogene Therapeutics, Novartis, Gilead, and Janssen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support